Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol - A double-masked, randomized, one-year study

被引:75
|
作者
Lass, JH
Eriksson, GL
Osterling, L
Simpson, CV
机构
[1] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH USA
[3] Pharmacia Corp, Uppsala, Sweden
关键词
D O I
10.1016/S0161-6420(00)00531-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To compare the long-term effects on corneal endothelial cell density and corneal thickness of latanoprost and the fixed combination latanoprost-timolol to timolol. Design: Double-masked, randomized, prospective, multicenter clinical trial. Participants: Three hundred sixty-nine subjects with bilateral ocular hypertension or open-angle glaucoma who had a baseline central corneal endothelial cell density of at least 1500 cells/mm(2), central corneal thickness of less than 0.68 mm, no corneal pathologic condition on slit-lamp examination, and intraocular pressure of less than 22 mmHg after a 3-week run-in on timolol, 0.5%, once daily were included. Intervention: Subjects were randomly assigned to treatment with latanoprost 0.005% (n = 127), fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116), or timolol 0.5% (n = 126) one drop, once daily in the morning for 1 year. All subjects were treated in both eyes. Specular microscopy and ultrasonic pachymetry were performed before treatment, and after 6 and 12 months of treatment. Main Outcome Measures: Mean percent change in central endothelial cell density and central corneal thickness after 1 year of treatment. Results: For both corneal endothelial cell density and corneal thickness, the mean percent changes from baseline were similar in all three treatment groups. Mean percent endothelial cell change at 1 year from baseline for latanoprost, FC, and timolol was 0.3 +/- 2.2%, 0.1 +/- 1.8%, 0.0 +/- 2.5% (mean +/- standard deviation; 95% confidence interval: latanoprost vs timolol -0.2-1.0; FC vs timolol -0.4-0.7) and mean percent change in corneal thickness was -1.1 +/- 2.5%, -1.0 +/- 2.0%, 0.2 +/- 3.1%, respectively. Conclusions: Latanoprost and FC are equivalent to timolol regarding long-term corneal effects after 1 year of treatment. Ophthalmology 2001;108:264-271 (C) 2001 by the American Academy of Ophthalmology.
引用
收藏
页码:264 / 271
页数:8
相关论文
共 50 条
  • [21] A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure.: A six month, evaluator masked, multicentre study in Europe
    García-Sánchez, J
    Rouland, JF
    Spiegel, D
    Pajic, B
    Cunliffe, I
    Traverso, C
    Landry, J
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (07) : 877 - 883
  • [22] A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma
    Parmaksiz, S
    Yüksel, N
    Karabas, VL
    Özkan, B
    Demirci, G
    Çaglar, Y
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2006, 16 (01) : 73 - 80
  • [23] Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
    Fechtner, Robert D.
    Harasymowycz, Paul
    Nixon, Donald R.
    Vold, Steven D.
    Zaman, Fiaz
    Williams, Julia M.
    Hollander, David A.
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 945 - 953
  • [24] Comparison of intraocular pressure lowering efficacy of fixed combination timolol-dorzolamide versus timolol plus latanoprost
    Lee, GC
    Katz, LJ
    Molineaux, J
    Fontanarosa, J
    Steinmann, WC
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [25] Dorzolamide/timolol fixed combination versus latanoprost:: Effects on intraocular pressure and hemodynamics
    Janulevicienë, I
    Harris, A
    Kagemann, L
    Siesky, B
    McCranor, L
    ISOPT: PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS, 2004, : 225 - 230
  • [26] Switching from latanoprost to fixed-combination latanoprot-timolol: A 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension
    Olander, K
    Zimmerman, TJ
    Downes, N
    Schoenfelder, J
    CLINICAL THERAPEUTICS, 2004, 26 (10) : 1619 - 1629
  • [27] Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension
    Suzuki, Katsuyoshi
    Otsuka, Naomi
    Hizaki, Hiroko
    Hashimoto, Masayo
    Kuwayama, Yasuaki
    ADVANCES IN THERAPY, 2018, 35 (06) : 796 - 808
  • [28] Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension
    Katsuyoshi Suzuki
    Naomi Otsuka
    Hiroko Hizaki
    Masayo Hashimoto
    Yasuaki Kuwayama
    Advances in Therapy, 2018, 35 : 796 - 808
  • [29] Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost
    Mulaney, J.
    Sonty, S.
    Ahmad, A.
    Stewart, J. A.
    Stewart, W. C.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2008, 18 (04) : 556 - 562
  • [30] Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension
    Katsuyoshi Suzuki
    Naomi Otsuka
    Hiroko Hizaki
    Masayo Hashimoto
    Yasuaki Kuwayama
    Advances in Therapy, 2019, 36 : 492 - 494